𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants

✍ Scribed by Subrat K. Panda; Rajagopal Ramesh; Kanury V. S. Rao; Asha Gupta; Arie J. Zuckerman; Nabeen C. Nayak

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
661 KB
Volume
35
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The immunogenicity of plasma‐derived (HB Vax, MSD) and recombinant hepatitis B virus (Engerix B, SKF) vaccines was evaluated in infants born to hepatitis B virus carrier mothers. The vaccination was carried out at 1 day, 1 month, and 6 months of age using 10 μg of the vaccine given intramuscularly. A total of 83/88 (94.3%) and 74/79 (93.6%) of the infants receiving the plasma‐derived vaccine and yeast‐derived vaccine showed antibody to hepatitis B surface antigen (anti‐HBs). None of the maternal factors studied apart from the HBeAg positivity corellated with vaccine failure. The yeast‐derived vaccine gives marginally lower antibody titre than the plasma‐derived vaccine. The group‐specific anti‐“a” antibody was less than 10% of the total anti‐HBsAg titre. It was observed that the vaccine alone without prior administration of hepatitis B immunoglobulin is effective in perinatal infection.

📜 SIMILAR VOLUMES

Recombinant-yeast-derived hepatitis b va
Recombinant-yeast-derived hepatitis b vaccine in healthy adults: Safety and two-year immunogenicity of early investigative lots of vaccine
✍ Lynn Butterly; Eloise Watkins; Jules L. Dienstag 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 554 KB

We tested the safety and long-term immunogenicity of two of the early investigative lots of a recombinant-yeast-derived hepatitis B vaccine in immunocompetent adults. Three 10-micrograms doses of recombinant hepatitis B vaccine (Merck Sharp & Dohme Research Laboratories, West Point, PA) were adminis

Five-year follow-up of a prospective ran
Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses
✍ Dr. Ching-Lung Lai; Benjamin Chun-Yu Wong; Eng-Kiong Yeoh; Wai-Ling Lim; Wai-Kwa 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 517 KB

In a prospective randomized trial, 318 children aged between 3 mo and 11 yr who were negative for all hepatitis B markers were randomized to receive two 5-pg doses of hepatitis B recombinant DNA yeast vaccine at 0 and 1 m o (group 11, three 5 -~g doses of hepatitis B recombinant DNA yeast vaccine at

Field evaluation of the efficacy and imm
Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants
✍ Alexander Milne; David J. West; Dang Van Chinh; Chris D. Moyes; Gabriele Poersch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract A study involving more than 2,000 infants was conducted in Vietnam to assess the field effectiveness and immunogenicity of recombinant hepatitis B vaccine given at birth, 1 month, 2 months, without concomitant hepatitis B immune globulin (HBIG). All received a 5 μg dose of H‐B‐VAX™II at

Immunogenicity of a yeast-recombinant he
Immunogenicity of a yeast-recombinant hepatitis B vaccine in high-risk children
✍ M. G. Rumi; R. Romeo; M. Bortolini; A. Gringeri; A. R. Zanett; P. M. Mannucci; M 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 391 KB

Horizontal transmission of hepatitis B virus (HBV) from illicit drug users to their contacts, including young children, can be prevented by active immunization against HBV. Yeast-recombinant hepatitis B vaccines are now available for this purpose, but their potential efficacy in such high-risk conta

Twelve-year follow-up of a prospective r
Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children
✍ Man-Fung Yuen; Wei-Ling Lim; Chi-Chung Cheng; Shiu-Kam Lam; Ching-Lung Lai 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 49 KB

A total of 318 children were prospectively randomized in group 1 with two 5-g doses of recombinant vaccine given at 0 and 1 month; in group 2 with three 5-g doses of recombinant vaccine given at 0, 1, and 6 months; or in group 3 with three doses of plasma-derived vaccine given at 0, 1, and 6 months.

Antibody responses of adults, adolescent
Antibody responses of adults, adolescents, and children to a plasma-derived hepatitis B vaccine in a rural African setting
✍ Dr. Edward Tabor; Robert J. Gerety; James Cairns; Anne C. Bayley 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

## Abstract A field trial of a plasma‐derived hepatitis B vaccine in five rural villages in Zambia was analyzed to determine if adults in a rural African setting respond to this vaccine as well as adults in Western countries and to determine the immunogenicity of fewer than the recommended three do